Introduction

Rare early onset lower urinary tract (REOLUT) disorders comprise not only gross anatomical malformations but also primary defects of functional maturation (Woolf et al, 2019). Although individually infrequent, these diseases are together a common cause of kidney failure in children and young adults (Harambat et al, 2012; Woolf, 2022; Pepper & Trompeter, 2022). REOLUT disorders can also have negative impacts on the self-esteem, education, and socialization of affected individuals (Pepper & Trompeter 2022; Hankinson et al, 2014). They have diverse phenotypes including: ureter malformations, such as megaureter; bladder malformations, such as exstrophy; and bladder outflow obstruction caused either by anatomical obstruction, as in urethral valves, or functional impairment of voiding without anatomical obstruction. The latter scenario occurs in urofacial, or Ochoa, syndrome (UFS) (Ochoa, 2004).

During healthy urinary voiding, the bladder outflow tract, comprising smooth muscle around the section of the urethra nearest the bladder, dilates while detrusor smooth muscle in the bladder body contracts. Conversely, in UFS, voiding is incomplete because of dyssynergia in which the outflow tract fails to fully dilate (Ochoa, 2004), and subsequent accumulation of urine in the LUT predisposes to urosepsis (Ochoa, 2004; Osorio et al, 2021). UFS is an autosomal recessive disease and around half of families studied genetically carry biallelic variants in HPSE2 (Daly et al, 2010; Pang et al, 2010; Newman & Woolf, 2018). Most are frameshift or stop variants, most likely null alleles, although missense changes, triplication and deletions have also been reported (Beaman et al, 2022). HPSE2 codes for heparanase-2 (McKenzie et al, 2000), also known as Hpa2, which inhibits endoglycosidase activity of the classic heparanase (Levy-Adam et al, 2010). Although subject to secretion (Levy-Adam et al, 2010; Beaman et al, 2022), heparanase-2 has also been detected in the perinuclear membrane (Margulis et al, 2021), suggesting yet-to-be defined functions there. The biology of heparanase-2 has been most studied in relation to oncology. For example, in head and neck cancers, heparanase-2 has anti-tumour effects, enhancing epithelial characteristics and attenuating metastasis (Gross-Cohen et al, 2021).

The autonomic nervous system controls voiding of the healthy bladder (Keast et al, 2015). In fetal humans and mice, heparanase-2 is immunodetected in bladder nerves (Stuart et al, 2013; Stuart et al, 2015). The protein is also present in pelvic ganglia near the bladder (Stuart et al, 2015; Roberts et al, 2019). These ganglia contain neural cell bodies that send autonomic effector axons into the bladder body and its outflow tract, with this neural network maturing after birth in rodents (Keast et al, 2015; Roberts et al, 2019). Mice carrying biallelic gene-trap mutations of Hpse2 have bladders that fail to fully void despite the absence of anatomical obstruction within the urethral lumen (Stuart et al, 2015; Guo et al, 2015). Although Hpse2 mutant mice do have pelvic ganglia, autonomic nerves implicated in voiding are abnormally patterned (Roberts et al, 2019). Ex vivo physiology experiments with Hpse2 mutant juvenile mice demonstrate impaired neurogenic bladder outflow tract relaxation (Manak et al, 2020), an observation broadly consistent with the functional bladder outflow obstruction reported in people with UFS (Ochoa, 2004). Therefore, while not excluding additional aberrations, such as a central nervous system defect (Ochoa, 2004), much evidence points to UFS featuring a genetic autonomic neuropathy affecting the bladder (Roberts & Woolf, 2020).

Recently, gene therapy has been used to treat animal models and human patients with previously incurable genetic diseases. Adeno associated virus 9 (AAV9) has been used as a vector in successful gene therapy for spinal muscular atrophy, an early onset genetic neural disease (Mendell et al, 2017). Here, we hypothesized that human HPSE2 gene therapy would restore autonomic nerve function in the bladder. Given that UFS is a neural disease, we elected to use AAV2/9 (simplified to AAV9) vector, which transduces diverse neural tissues in mice (Foust et al, 2009), although uptake into the pelvic ganglia has not been reported. We administered AAV9 vector carrying human HPSE2 to neonatal mice, in the first day after birth when bladder neural circuitry is maturing. Several weeks later, evidence of transgene transduction and expression were sought and therapeutic effects on neuropathic dysfunction were investigated in smooth muscle relaxation of the bladder outflow tract and smooth muscle contractility of the bladder body.

Results

Administration of AAV9/HPSE2 to WT mice

We undertook exploratory experiments in WT mice, primarily to determine whether the viral vector was capable of transducing pelvic ganglia after neonatal intravenous injection. We also wished to determine whether administration of AAV9/HPSE2 was compatible with normal postnatal growth and general health. Given that human gene therapy with AAV9 vectors have been associated with a specific side-effect, liver damage (Mendell et al, 2017), and the recent implication of AAV2 in community acquired hepatitis (Ho et al, 2023), we also examined mouse livers at the end of the experiment. To determine efficacy of transduction, neonatal WT mice were administered the AAV9/HPSE2 vector, and they were followed until they were young adults (Figure 1a). Previous studies administering AAV9 carrying reporter genes to neonatal mice have used single doses of up to 10¹² genome copies (Foust et al, 2009; Buckinx et al, 2016). In the current experiments, because the AAV9/HPSE2 vector was yet to be tested in vivo, we took a cautious approach, assessing single doses of 2×10¹⁰ or 1×10¹¹ genome copies. WT neonatal mice administered either dose gained body weight in a similar manner to WT mice injected with vehicle only (Figure 1b). Moreover, throughout the five-week observation period, AAV9/HPSE2 administered mice displayed normal general appearances and behaviour (e.g., condition of skin and fur, ambulation, grooming, and feeding). As outlined in the Introduction, evidence points to UFS being an autonomic neuropathy of the bladder. Therefore, we determined whether the AAV9/HPSE2 vector had targeted pelvic ganglia that flank the base of the mouse bladder (Keast et al, 2015; Roberts et al, 2019).

Figure 1.

To seek the transduced vector genome, tissue sections were stained using Basescope ISH for the WPRE3 genomic sequence (Figure 1c, upper panels). The regulatory element was detected in neural cell bodies of ganglia of five-week-old mice that had been administered either dose of AAV9/HPSE2, while no signal was detected in ganglia of vehicle-only injected mice. Of 42 ganglion cells imaged from three mice injected with the 2×10¹⁰ dose, and 71 ganglion cells imaged from three mice injected with the 10¹¹ dose, 45% were positive in each group. Here, the definition of positive was at least one red dot in a cell. The transduced cargo was expressed, as indicated by reaction with the human HPSE2 mRNA probe (Figure 1c). No signal was detected in mice that received vehicle-alone. In contrast, HPSE2 transcripts were detected in pelvic ganglia of mice that had been administered AAV9/HPSE2. Of 44 ganglion cells imaged from three mice injected with the 2×10¹⁰ dose, 11% were positive; and of 57 ganglion cells imaged from three mice injected with the 10¹¹ dose, 40% were positive. Moreover, although not quantified, the intensity of expression within positive cells appeared greater in the higher dose group (Figure 1c).

Liver sections (Figure 2) were assessed for WPRE3 Basescope signals by counting the number of red dots per unit area. The average density measured in sections from three mice injected with 2×10¹⁰ vector was 587/mm², compared with 835/mm² for 3 mice injected with 2×10¹¹ vector, while sections from vehicle-injected mice showed no signal. Assessing HPSE2 Basescope signals, the density averaged 45/mm² for three mice injected with 2×10¹⁰ vector, 680/mm² for three mice injected with 2×10¹¹ vector and zero for vehicle-injected mice. PSR-stained liver sections, imaged with bright-field and polarised light are illustrated in Figure 2b. The birefringence under polarised light, indicating collagen fibres, was measured as the percentage of the field of view it occupied (Figure 2c). There was no significant difference among the three animal groups in the amount of collagen present, suggesting that neonatal administration of AAV9/HPSE2 was not associated with liver fibrosis when assessed in mouse early adulthood.

Figure 2.

Administration of AAV9/HPSE2 to Hpse2 Mut mice

Having demonstrated the feasibility and general safety of the procedure in WT mice, a second set of experiments were undertaken to determine whether administration of AAV9/HPSE2 to Mut mice would ameliorate aspects of their bladder pathophysiology (Figure 3a). Reasoning that the higher dose AAV9/HPSE2 (1×10¹¹ genome copies) had been well-tolerated in our scoping experiments in WT mice, we used it here. As expected (Stuart et al, 2015), untreated Mut mice gained significantly less body weight than sex-matched WT mice over the observation period (Figure 3b). Administration of AAV9/HPSE2 to Mut mice did not significantly modify their impaired growth trajectory (Figure 3b). On autopsy, bladders of untreated Mut mice appeared distended with urine (Figure 3c and d), consistent with bladder outflow obstruction, and confirming a previous report (Stuart et al, 2015). In contrast, only one of nine bladders of Mut mice that had been administered AAV9/HPSE2 appeared distended (Figure 3c and d). The remainder had autopsy bladder appearances similar to those reported for WT mice (Stuart et al, 2015). Bladder bodies were then isolated, drained of urine, and weighed. The bladder body/whole mouse weight (Figure 3e) of Mut mice that had not received AAV9/HPSE2 was significantly higher than untreated WT mice. While values in AAV9/HPSE2- administered Mut mice (median 0.0016, range 0.0010 to 0.0139) tended to be higher than those of untreated WT mice, they were not significantly different from these controls.

Figure 3.

Histology sections of pelvic ganglia were reacted with Basescope probes (Figure 4). Using the WPRE3 genomic probe, no signals were detected in either WT or Mut mice that had not received the viral vector (Figure 4a and c). In contrast, signals for WPRE3 were detected in WT and Mut mice administered AAV9/HPSE2 as neonates (Figure 4b and d). Using the human HPSE2 probe, no transcripts were detected in ganglia of WT and Mut mice (Figure 4e and g). In contrast, signals for HPSE2 were detected in WT and Mut mice administered AAV9/HPSE2 as neonates (Figure 4f and h). In sections from AAV9/HPSE2-administered WT mice (n=3), 63% of 185 ganglion cells were positive for WPRE3, and 56% of 210 cells expressed HPSE2. In AAV9/HPSE2-administered Mut mice (n=3 assessed), 74% of 167 ganglion cells were positive for WPRE3, and 68% of 191 cells expressed HPSE2. Heparanase-2 was sought with an antibody reactive to both human and mouse protein (Figure 4i-l), with consistent findings in three mice examined in each experimental group. The protein was detected in pelvic ganglia of untreated WT mice, but only a faint background signal was noted in ganglia of untreated mutant. Heparanase-2 was detected in ganglia of both WT and Mut mice that had been administered the vector.

Figure 4.

The vector genome sequence WPRE3, and HPSE2 transcripts, were also detected in livers of WT and Mut mice that had been administered the vector (Figure 5a). The average number of vector (red dots per area of liver section) from three livers of WT mice injected with AAV9/HPSE2 were 201/mm² for WPRE3 and 30/mm² for HPSE2. The average values from three Mut mice injected with the AAV9/HPSE2 were 293/mm² for WPRE3 and was 172/mm² for HPSE2. There was no sign of pathological fibrosis in the livers of these mice, as assessed by PSR staining and birefringence quantified under polarised light (Figure 5b and c). Kidneys were also analysed using histology but neither the WPRE3 sequence nor HPSE2 transcripts were detected in glomeruli or tubules (Figure 6).

Figure 5.

Figure 6.

HPSE2 gene transfer ameliorates bladder pathophysiology in Hpse2 mutant males

We proceeded to undertake ex vivo physiology experiments using myography, with isolated bladder outflow tracts and isolated bladder bodies studied separately. No significant differences in contraction amplitudes induced by 50 mM KCl were documented comparing WT outflow tracts with Mut tissues of mice that had either been administered, or had not been administered, AAV9/HPSE2 (Figure 7a). Male outflow tracts were pre-contracted with PE, and then subjected to EFS. Nerve-mediated relaxation of pre-contracted outflow tracts had been reported to be impaired in juvenile male Mut mice (Manak et al, 2020). Accordingly, as expected, in the current study neurogenic relaxation of outflow tracts from untreated Mut mice was significantly less than WT relaxation (Figure 7b and c). For example, the average Mut relaxation at 15 Hz was around a third of the WT value. In outflow tracts from AAV9/HPSE2-administered Mut mice, however, EFS-induced relaxation was no longer significantly different to WT controls, and it was three-fold greater than in untreated Mut mice (Figure 7b and c).

Figure 7.

Next, male bladder body rings were studied using myography (Figure 7d-g). Application of EFS caused detrusor contractions of isolated bladder body rings. In samples from mice that had not received AAV9/HPSE2 as neonates, contractions were significantly lower in Mut than in WT preparations (Figure 7d and e). For example, at 25 Hz the average Mut value was half of the WT value. Strikingly, however, the contractile response to EFS increased around 2.5-fold in Mut bladder rings from AAV9/HPSE2-administered mice compared with untreated Mut mouse bladder rings (Figure 7d and e). Indeed, EFS-induced DSM contractions in treated Mut mice were not statistically different to those of WT mice (Figure 7e). No significant difference in contraction amplitude to 50 mM KCl was documented comparing WT samples with tissues isolated from either vector administered or untreated Mut mice (Figure 7f). As previously reported (Manak et al, 2020), bladder body contractions in response to cumulative increasing concentrations of carbachol were significantly higher in untreated Mut tissues in comparison with WT bladder rings (Figure 7g). Bladder body samples from AAV9/HPSE2-administered Mut mice showed an attenuated hyper-response to carbachol, and values in this treated Mut group were no longer significantly different to the WT response (Figure 7g).

HPSE2 gene transfer ameliorates bladder pathophysiology in Hpse2 mutant females

UFS affects both males and females (Ochoa, 2004; Newman & Woolf 2018), yet results of ex vivo physiology have to date only been reported in tissues from Hpse2 mutant male mice (Manak et al, 2020). Therefore, we proceeded to study outflow tracts and bladder bodies from female Mut mice by ex vivo myography (Figure 8a-g). No significant difference in contraction amplitude to 50 mM KCl was documented comparing WT outflow tracts with Mut tissues from mice that had either been administered, or not been administered, AAV9/HPSE2 (Figure 8a). Female outflow tracts were pre-contracted with vasopressin because they do not respond to PE, the α1 receptor agonist (Grenier et al, 2023). In the current study, therefore, vasopressin was used to pre-contract female outflow tracts before applying EFS. Such samples from untreated Hpse2 female mutant mice showed significantly less relaxation than WT outflow tracts (Figure 8 b and c), with a striking twenty-fold reduction at 15 Hz. Outflow tract preparations from female Mut mice that had been administered AAV9/HPSE2, however, displayed EFS-induced relaxation that was not significantly different to WT samples (Figure 8 b and c). Indeed the relaxation response of treated Mut samples was significantly increased compared with untreated Mut mice, with an average twelve-fold increase in relaxation at 15 Hz (Figure 8c).

Figure 8.

Next, female bladder body rings were studied with myography (Figure 8d-g). Applying EFS caused contractions of isolated bladder body rings (Figure 8d and e). In preparations from animals that had not received AAV9/HPSE2 as neonates, contractions were significantly lower in Mut than in WT preparations, being reduced seven-fold at 25 Hz. Strikingly, however, the contractile detrusor response to EFS in Mut bladder rings from mice that had received AAV9/HPSE2 was significantly greater than samples from untreated Mut mice, with a five-fold increase at 25 Hz. However, the bladder body contractions in AAV9/HPSE2-administered Mut mice were still significantly smaller than those in WT mice (Figure 8e). No significant difference in contraction amplitude to 50 mM KCl was documented comparing the three bladder body groups (Figure 8f). Unlike the enhanced contractile response to carbachol in male Mut bladder rings, detailed above, female bladder rings showed similar responses to carbachol in each of the three experimental groups (Figure 8g).

Discussion

Currently, no treatments exist that target the primary biological disease mechanisms underlying REOLUT disorders. Interventions for UFS are limited and include catheterization to empty the bladder, drugs to modify smooth muscle contractility, and antibiotics for urosepsis (Ochoa, 2004; Newman & Woolf, 2018; Osorio et al, 2021). Moreover, surgery to refashion the LUT in UFS is either ineffective or even worsens symptoms (Ochoa, 2004). Given that some REOLUT disorders have defined monogenic causes, it has been reasoned that gene therapy might be a future option, but the strategy must first be tested on genetic mouse models that mimic aspects of the human diseases (Lopes et al, 2021). The results presented in the current study constitute first steps towards curing UFS, a clinically devastating genetic disease featuring a bladder autonomic neuropathy.

We report several novel observations. First, female Hpse2 mutant mice have neurogenic defects in outflow tract relaxation and detrusor contraction that are similar to those reported for male Hpse2 mutant mice (Manak et al, 2020). This sex equivalence in the mouse model is an important point because UFS affects both males and females (Newman and Woolf, 2018). On the other hand, we observed nuanced differences between the mouse sexes. For example, regarding bladder bodies, females displayed a more profound defect in contractions elicited by EFS, while they lacked the hyper-sensitivity to carbachol shown by males. Second, we have demonstrated that an AAV can be used to transduce pelvic ganglia that are key autonomic neuronal structures in the pathobiology of UFS. Importantly, the neuro-muscular circuitry of the bladder matures over the first three postnatal weeks in murine species (Keast et al, 2015). A single dose of 1×10¹¹ genome copies of AAV9/HPSE2 was sufficient to transduce around half of neural cell bodies in these ganglia, when assessed in the third postnatal week. It is possible that the administration of a higher dose of the vector would have resulted in a higher percent of positive cell bodies. Strikingly, heparanase-2 became detectable in pelvic ganglia of treated Mut mice. Our third key observation is that the 1×10¹¹ dose significantly ameliorated defect in the mutant LUT, despite not every neural cell body being transduced. On autopsy, untreated Mut mice had distended urinary bladders, consistent with bladder outflow obstruction, but AAV9/HPSE2-administered mice did not, thus resembling wild-type mice. AAV9/HPSE2 significantly ameliorated the impaired neurogenic relaxation of outflow tracts and the impaired neurogenic contractility of mutant detrusor smooth muscle found in Hpse2 Mut mice. In future, it will be important to study whether the gene transfer strategy might also ameliorate a dyssynergia between bladder and outflow as assessed by in vivo cystometry (Ito et al, 2018). These complex in vivo experiments are, however, beyond the remit of the current work.

A feature of the current mouse model, also observed in a different Hpse2 gene trap mouse (Guo et al, 2015), is the poor whole body growth compared with WT controls. This becomes more marked during the first month of life and, in the current study, it was not ameliorated by neonatal AAV9/HPSE2 administration. The cause of the growth impairment has not been established, but, as demonstrated in the current study, is not accompanied by structural kidney damage. Moreover, our unpublished observations found that Hpse2 mutant pups appear to feed normally, as assessed by finding their stomachs full of mother’s milk. Histological examination of their lungs is normal, excluding aspiration pneumonia. Whatever the cause of the general growth failure, it is notably dissociated from the LUT phenotype, given that AAV9/HPSE2 administration corrects bladder pathophysiology but not overall growth of the mutant mouse.

A small subset of individuals with UFS carry biallelic variants of leucine rich repeats and immunoglobulin like domains 2 (LRIG2) (Stuart et al, 2013; Grenier et al, 2023). LRIG2, like heparanase-2, is immunodetected in pelvic ganglia (Stuart et al, 2013; Roberts et al, 2019). Moreover, homozygous Lrig2 mutant mice have abnormal patterns of bladder nerves and display ex vivo contractility defects in LUT tissues compatible with neurogenic pathobiology (Roberts et al, 2019; Grenier et al, 2023). In future, the neonatal gene therapy strategy outlined in the current paper could be applied to ameliorate bladder pathophysiology in Lrig2 mutant mice. As well as in UFS, functional bladder outflow obstruction occurs in some individuals with prune belly syndrome (Volmar et al, 2001) and in megacystis microcolon intestinal hypoperistalsis syndrome (Gosemann et al, 2011). Moreover, apart from UFS, functional bladder outflow obstruction can be inherited as a Mendelian trait and some such individuals carry variants in genes other than HPSE2 or LRIG2. These other genes are implicated in the biology of bladder innervation, neuro-muscular transmission, or LUT smooth muscle differentiation (Weber et al, 2011; Caubit et al, 2016, Woolf et al, 2019; Houweling et al, 2019; Mann et al, 2019; Beaman et al, 2019; Hahn et al, 2022). Genetic mouse models exist for several of these human diseases and, again, could be used as models for gene therapy.

There are numerous challenges in translating work in mouse models to become effective therapies in humans. First, neonatal mice are immature compared to a newborn person, and the anatomy of their still developing kidneys and LUTs can be compared to those organs in the human fetus in the late second trimester (Woolf & Lopes, 2023). Thus, gene replacement therapy for people with UFS and related genetic REOLUT disorders may need to be given before birth. In fact, UFS can present in the fetal period when ultrasonography reveals a dilated LUT (Newman & Woolf, 2018; Grenier et al, 2023). The ethics and feasibility of delivering genes and biological therapies to human fetuses are current topics of robust debate (Sagar et al, 2020; Mimoun et al, 2023) and, with advances in early detection and therapies themselves, may become established in coming years. Second, there are concerns about possible side-effects of administering AAV vectors (Srivastava et al, 2023). Factoring weight for weight, the dose of AAV9 vector administered to the Hpse2 mutant mice in the current study is of a similar order of magnitude as those used to treat babies with spinal muscular atrophy (Mendell et al, 2017). In that report there was evidence of liver damage, as assessed by raised blood transaminases in a subset of treated patients. In the current mouse study, we found that the viral vector transduced livers, while kidneys were resistant to transduction. As assessed by histological analyses to seek fibrosis, livers from AAV9/HPSE2 treated mice appeared normal.

We cannot, however, exclude transient liver damage, which could be assessed by alterations in blood transaminases. The fact that transduced livers expressed HPSE2 transcripts, and the observation that heparanse-2 is a secreted protein (Levy-Adam et al, 2010; Beaman et al, 2022), raises the possibility that livers of treated mice may act as a factory to produce heparanase-2 that then circulated and had beneficial effects on the LUT, akin to gene therapy to replace coagulation factors missing in haemophilia (Chowdary et al, 2022).

In summary, we have used a viral vector-mediated gene supplementation approach to ameliorate tissue-level neurophysiological defects in UFS mouse bladders. This advance provides a proof-of-principle to act as a paradigm for treating other genetic mouse models of REOLUT disorders. In the longer term, application to humans may need to consider fetal therapy, for reasons detailed above.

Methods

Experimental strategy

In a first set of experiments to explore the feasibility of transducing pelvic ganglia, neonatal homozygous wild-type (WT), mice were intravenously administered the AAV9/HPSE2 vector (described below). These mice were observed until they were young adults when their internal organs were collected to seek evidence of transgene transduction and expression. Next, we determined whether neonatal administration of AAV9/HPSE2 to homozygous Hpse2 mutant mice, hereafter called Mut, would ameliorate ex vivo bladder physiological defects that had been described in juvenile Hpse2 mutants (Manak et al, 2020). The third postnatal week was used as the end point, because Hpse2 Mut mice subsequently fail to thrive (Stuart et al, 2015) and ex vivo physiological bladder aberrations have been characterised in Mut mice of a similar age (Manak et al, 2020).

The viral vector

The custom made (Vector Biolabs) AAV9 vector carried the full-length coding sequence for human HPSE2 and the broadly active synthetic CMV early enhancer/chicken Actb (CAG) promoter. This promoter has been used successfully in human gene therapy for spinal muscular atrophy (Mendell et al., 2017). The construct also contained the woodchuck hepatitis virus post-transcriptional regulatory element (WPRE3), known to create a tertiary structure that increases mRNA stability and thus potentially enhancing biological effects of genes delivered by viral vectors (Loeb et al, 1999; Lee et al, 2005), and flanking AAV2 inverted terminal repeat (ITR) sequences.

Experimental mice

Mouse studies were performed under UK Home Office project licenses PAFFC144F and PP1688221. Experiments were undertaken mindful of ARRIVE animal research guidelines (Percie du Sert et al, 2020). C57BL/6 strain mice were maintained in a 12-hour light/dark cycle in the Biological Services Facility of The University of Manchester. The mutant allele has the retroviral gene trap VICTR4829 vector inserted into intron 6 of Hpse2 (Stuart et al, 2015) (mouse accession NM_001081257, and Omnibank clone OST441123). The mutation is predicted to splice exon 6 to a Neo cassette and generate a premature stop codon. Accordingly, homozygous mutant mouse bladder tissue contains a truncated Hpse2 transcript and lacks full length Hpse2 transcripts extending beyond the trap (Stuart et al, 2015). Mating heterozygous parents leads to the birth of WT, heterozygous, and Mut offspring in the expected Mendelian ratio (Stuart et al, 2015). In the first month after birth Mut mice gain less weight than their WT littermates (Stuart et al, 2015) and, because they later fail to thrive, Mut mice are culled around a month of age before they become overtly unwell. Application of tattoo ink paste (Ketchum, Canada) on paws of neonates (i.e., in the first day after birth) was used to identify individual mice, and same-day genotyping was undertaken. This was carried out using a common forward primer (5′CCAGCCCTAATGCAATTACC3′) and two reverse primers, one (5′TGAGCACTCACTTAAAAGGAC3′) for the WT allele and the other (5′ATAAACCCTCTTGCAGTTGCA3′) for the gene trap allele. Neonates underwent general anaesthesia with 4% isoflurane, and AAV9/HPSE2 suspended in up to 20 μl of sterile phosphate buffered saline (PBS) was injected into the temporal vein. This procedure took around two minutes, after which the baby mice were returned to their mother. Control neonates received either vehicle-only (PBS) injection or were not injected. At the end of the study, mice underwent Schedule 1 killing by inhalation exposure to a rising concentration of carbon dioxide followed by exsanguination.

Bladder outflow tract and bladder body myography

Ex vivo myography and its interpretation were undertaken using methodology detailed in previous studies (Manak et al, 2020; Grenier et al, 2023). Functional smooth muscle defects of both the outflow tract and bladder body were previously characterised in juvenile Hpse2 Mut mice (Manak et al, 2020), so mice of the same age were used here. Outflow tracts, which contained SM but not the external sphincter, were separated from the bladder body by dissection. Intact outflow tracts or full thickness rings from the mid-portion of bladder bodies, containing detrusor smooth muscle, were mounted on pins in myography chambers (Danish Myo Technology, Hinnerup, Denmark) containing physiological salt solution (PSS) at 37°C. The PSS contained 122 mM NaCl, 5 mM KCl, 10 mM N-2-hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES), 0.5 mM KH₂PO₄, 1 mM MgCl₂, 5 mM D-glucose and 1.8mM CaCl₂ adjusted to pH 7.3 with NaOH.

The contractility of outflow tract and bladder body preparations was tested by applying 50 mM KCl to directly depolarise SM and stimulate Ca²⁺ influx through voltage gated Ca²⁺ channels. Sympathetic stimulation of α-1 adrenergic receptors mediates urethral contraction in male mice and primates but has little effect in females (Alexandre et al, 2017). The α-1 adrenergic receptor agonist, phenylephrine (PE, 1 μM), was therefore used to contract male outflow tracts before applying electrical field stimulation (EFS; 1 ms pulses of 80 V at 0.5–15 Hz for 10 s) to induce nerve-mediated relaxation. Female outflow tracts were instead pre-contracted with vasopressin (10 nM) as previously detailed (Grenier et al, 2023), because they are known to express contractile arginine-vasopressin (AVP) receptors (Zeng et al, 2015). Bladder body rings were subjected to EFS (1 ms pulses of 80V at 0.5–25 Hz for 10 s) to induce frequency-dependent detrusor contractions. As these contractions are primarily mediated by acetylcholine, through its release from parasympathetic nerves and binding to muscarinic receptors (Matsui et al, 2002), we also measured the degree of bladder body contractions evoked directly by the muscarinic agonist, carbachol (10 nM – 50 μM).

Histology

Samples of liver, kidney and pelvic ganglia flanking the base of the mouse bladder (Keast et al, 2015; Roberts et al, 2019) were removed immediately after death and prepared for histology. Tissues were fixed in 4% paraformaldehyde, paraffin-embedded and sectioned at 5 μm for bladders and kidneys, or 6 μm for livers. After dewaxing and rehydrating tissue sections, BaseScope^TM probes (ACDBio, Newark, CA, USA) were applied. In situ hybridisation (ISH) was undertaken, using generic methodology as described (Lopes et al, 2019). To seek expression of transduced HPSE2, BA-Hs-HPSE2-3zz-st designed against a sequence in bases 973-1102 in exons 5–7 was used. Other sections were probed for the widely expressed PPIB transcript encoding peptidylprolyl isomerase B (BaseScope™ Positive Control ProbeMouse (Mm)-PPIB-3ZZ 701071). As a negative control, a probe for bacterial dapB (BaseScope™ Negative Control ProbeDapB-3ZZ 701011) was used (not shown). We also used a BaseScope ISH probe to seek genomic WPRE3 delivered by the viral vector (cat. 882281). BaseScope detection reagent Kit v2-RED was used following the manufacturer’s instructions, with positive signals appearing as red dots within cells. Gill’s haematoxylin was used as a counterstain. Images were acquired on a 3D-Histech Pannoramic-250 microscope slide-scanner using a 20×/ 0.80 Plan Apochromat (Zeiss). Snapshots of the slide-scans were taken using the Case Viewer software (3D-Histech). Higher powered images were acquired on an Olympus BX63 upright microscope using a DP80 camera (Olympus) through CellSens Dimension v1.16 software (Olympus). For immunohistochemistry, after dewaxing and rehydration, endogenous peroxidase was quenched with hydrogen peroxide. Slides were microwaved and then cooled at room temperature for 20 min in antigen-retrieval solution (10 mM sodium citrate, pH 6.0). A primary antibody raised in rabbit against heparanase-2 (Abcepta AP12994c; 1:400) was applied. The immunogen was a KLH-conjugated synthetic peptide between 451-480 amino acids in the C-terminal region of human heparanase-2, predicted to cross-react with mouse heparanase-2. The primary antibody was prepared in PBS Triton-X-100 (0.1%) and 3% serum and incubated overnight at 4 °C. It was reacted with a second antibody and the positive brown signal generated with DAB peroxidase-based methodology (Vector Laboratories, SK4100). Sections were counterstained with haematoxylin alone, or haematoxylin and eosin. Omission of the primary antibody was used as a negative control. Some liver sections were also reacted with 1% picrosirius red (PSR) solution (diluted in 1.3% picric acid) for one hour. Birefringent collagen was visualised under cross-polarised light and the percentage of area covered by birefringence measured as described (Hindi et al, 2021).

Statistics

Data organised in columns are expressed as mean±SEM and plotted and analysed using the GraphPad Prism 8 software. The Shapiro-Wilk test was used to assess normality of data distributions. If the values in two sets of data passed this test and they had the same variance, a Student t-test was used to compare them. If the variance was different, a t-test with Welch’s correction was used. If data did not pass the normality test, a non-parametric Mann-Whitney test was used. Groups of data with repeated measurements (e.g. at different stimulation frequencies or concentration) were compared using 2-way ANOVA with repeated measures. An F-test was used to assess the likelihood that independent data sets forming concentration-response relationships were adequately fit by a single curve.

Disclosure

The authors declare no conflicts of interest.

Acknowledgements

We acknowledge receiving research funding from: Medical Research Council (project grant MR/L002744/1 to ASW and WGN; project grant MR/T016809/1 to ASW, NAR, and FML; and Doctoral Training Programme studentship to BWJ); Kidney Research United Kingdom (project grant Paed_RP/002/20190925 to WGN, GMB, and ASW; and Paed_RP/005/20190925 to NAR and ASW); Newlife Foundation (project grants 15-15/03 and 15-16/06 to WGN and ASW); the Manchester NIHR Biomedical Research Centre (IS-BRC-1215-20007 to WGN); and Kidneys for Life (start-up grant 2018 to NAR, and project grant to NAR 2023); a LifeArc Pathfinder Award (to NAR, ASW, CG, WGN); and an MRC-NIHR UK Rare Disease Research Platform MR/Y008340/1 to NAR, ASW, WGN. We thank the Manchester NIHR Biomedical Research Centre Rare Diseases theme, and the Manchester Rare Condition Centre for support.